Thyrocare Technologies Limited — Updates, 23-04-2025: Press Release

Thyrocare Technologies Limited reported a consolidated revenue of INR 187.2 Cr for the quarter ended March 31, 2025, reflecting a 21% year-over-year increase, driven by 23% growth in its Pathology segment and 7% in Radiology. The total testing volume reached 167.9 million, the highest to date. Franchise revenue grew 22% YoY, while partnership revenue increased by 24%. The consolidated gross margin improved to 74%, with a normalized EBITDA margin of 35%. Standalone normalized EBITDA and PAT surged by 72% YoY, while consolidated normalized EBITDA and PAT saw remarkable increases of 78% and 88% YoY, respectively. The company has proposed a final dividend of INR 21 per equity share, pending approval. Cash reserves as of March 2025 stood at INR 191.8 Cr, following the opening of new labs in Bhagalpur and Kashmir. Overall, Thyrocare's solid performance positions it well for future growth, warranting close monitoring from investors.